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Abstract
Purpose Women’s worry about developing breast cancer may influence their decision to use preventive therapy. However, 
the direction of this relationship has been questioned. We prospectively investigated the relationship between breast cancer 
worry and uptake of preventive therapy. The socio-demographic and clinical factors associated with high breast cancer worry 
were also investigated.
Methods Women at increased risk of developing breast cancer were recruited from clinics across England (n = 408). Par-
ticipants completed a survey on their breast cancer worry, socio-demographic and clinical factors. Uptake of tamoxifen was 
recorded at 3 months (n = 258 women, 63.2%). Both primary and sensitivity analyses were conducted using different clas-
sifications of low, medium and high worry.
Results 39.5% of respondents reported medium breast cancer worry at baseline and 21.2% reported high worry. Ethnic 
minority women were more likely to report high worry than white women (OR = 3.02, 95%CI 1.02, 8.91, p = 0.046). Women 
educated below degree level were more likely to report high worry than those with higher education (OR = 2.29, 95%CI 1.28, 
4.09, p = 0.005). No statistically significant association was observed between worry and uptake. In the primary analysis, 
fewer respondents with medium worry at baseline initiated tamoxifen (low worry = 15.5%, medium = 13.5%, high = 15.7%). 
In the sensitivity analysis, participants with medium worry reported the highest uptake of tamoxifen (19.7%).
Conclusions No association was observed between worry and uptake, although the relationship was affected by the cat-
egorisation of worry. Standardised reporting of the classification of worry is warranted to allow transparent comparisons 
across cohorts.
Keywords Preventive therapy · Chemoprevention · Decision-making · Cancer worry
Introduction
Breast cancer incidence is rising worldwide [1]. There is 
increasing interest in preventive therapy for people at higher 
risk of cancer as part of prevention efforts [2, 3]. The UK 
National Institute of Health and Care Excellence (NICE) 
considers women with a lifetime breast cancer risk of 
17–30% to be at moderately high risk, and those exceeding 
30% to be high risk [4, 5]. In a meta-analysis of nine ran-
domised control trials, selective oestrogen receptor modu-
lators (SERMs) reduced the incidence of breast cancer by 
at least 30% among women at increased risk [6]. In 2013, 
NICE published clinical guidelines (CG164) recommending 
SERMs (e.g. tamoxifen) are offered to higher-risk women 
with a family history of breast cancer [4].
Following the introduction of the NICE guidance 
(CG164), a UK prospective study reported low uptake of 
tamoxifen (14.7%) among women at increased risk of breast 
cancer [7]. Worry about developing breast cancer may influ-
ence women’s decision to use preventive therapy. Previous 
cross-sectional studies found women reporting higher levels 
of breast cancer worry were more likely to be interested in 
using preventive therapy [8, 9]. Prospective US studies have 
also observed an association between breast cancer worry 
and uptake of preventive therapy [10, 11]. These findings 
suggest women who worry more about developing breast 
cancer may be more likely to use preventive therapy. How-
ever, there are mixed results on the direction of this relation-
ship [12].
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There may be an inverted U-shaped relationship between 
breast cancer worry and uptake of preventive therapy, 
whereby moderate levels of worry are most strongly asso-
ciated with uptake. An inverted U-shaped relationship has 
been observed between breast cancer worry and other can-
cer protective behaviours, such as screening [13–16]. These 
findings suggest people with moderate worries about devel-
oping breast cancer are more likely to engage with preven-
tive behaviours, compared with those reporting lower or 
higher worries. Few prospective studies have investigated 
whether there is a U-shaped relationship between breast 
cancer worry and uptake of preventive therapy. Given the 
negative psychological side effects of worry [17], identify-
ing those who experience cancer-related worry is warranted. 
Previous data also indicate people from lower socioeco-
nomic status (SES) backgrounds [18], and ethnic minority 
respondents [18, 19] are more likely to experience higher 
levels of cancer worry.
We assessed levels of breast cancer worry among women 
considering preventive therapy in a UK clinical practice 
setting and investigated whether there was an association 
between worry and uptake. We also investigated the socio-
demographic and clinical factors associated with higher 
worry, and assessed whether worry changed over time. This 
analysis is part of the ENGAGE study; a multicentre pro-
spective investigation of preventive therapy uptake in Eng-
land among women at increased risk of breast cancer [7, 20].
Methods
Recruitment
Twenty clinics in England supported recruitment between 
September 2015 and December 2016. This included family 
history clinics (n = 12), breast clinics (n = 4), clinical genetic 
centres (n = 3) and a family history clinic with genetics sup-
port (n = 1). After a clinic appointment, a healthcare profes-
sional approached the woman to discuss the study. Women 
who verbally consented were given a study pack containing 
the baseline survey. Informed consent was implied following 
the return of the survey. An identification code was assigned 
to participants who verbally consented, which was linked to 
their baseline survey. After verbal consent, women’s per-
sonal data were sent to the study team via a secure online 
portal. These data included: patients age, email address, 
home address and their risk classification (‘moderately high’ 
or ‘high’). At 3 months, baseline survey respondents were 
sent a follow-up survey.
The ENGAGE study was granted ethical approval by the 
National Research Ethics Service Committee North West—
Preston (14/NW/1408). Women were eligible to participate 
if they were over the age of 18, classified as ‘moderately 
high’ or ‘high’ risk of breast cancer, spoke English, had dis-
cussed preventive therapy with a healthcare professional and 
had no known contraindications for tamoxifen use. Women 
were excluded if they were unable to consent or had a previ-
ous breast cancer diagnosis.
Measures
The baseline survey contained measures of socio-demo-
graphic and clinical factors, and breast cancer worry. The 
follow-up survey measured uptake of tamoxifen and breast 
cancer worry at 3 months. The time period between the base-
line and follow-up survey was decided on the basis that this 
was a reasonable amount of time for participants to consider 
the harms and benefits of tamoxifen, and to have spoken 
with a GP about obtaining a prescription.
Socio‑demographic and clinical factors
The baseline survey contained items on demographic and 
socioeconomic factors, some of which were dichotomised 
in the analysis. These measures included nulliparity (yes 
vs. no), marital status (married/cohabiting vs. single/
divorced/separated/widowed), education level (≥ degree 
level vs. < degree level), ethnicity (white ethnic groups vs. 
ethnic minority groups), employment status (full-time vs. 
all other employment types) and self-reported health (poor, 
fair, good, excellent). Age was calculated from date of birth 
provided from National Health Service (NHS) records, with 
age recoded to ≤ 35 years; 36–49 years and; ≥ 50 years. Post-
codes were used to calculate a participant’s Index of Mul-
tiple Deprivation (IMD) score, and women were classified 
into tertiles of neighbourhood deprivation (low, middle and 
high) [21]. Breast cancer risk category, based on the NICE 
guideline CG164 [4], was provided by staff at the clinic they 
had attended.
Breast cancer worry
Two items measured breast cancer worry, which were 
adapted from the Lerman Breast Cancer Worry Scale [16]. 
Respondents were asked to assess how frequently each state-
ment was true for them over the past 7 days. The statements 
were ‘I worried about developing breast cancer’ and ‘My 
worries about breast cancer interfered with my daily activi-
ties’. Each item was assessed on a 4-point Likert scale: ‘Not 
at all’, ‘Rarely’, ‘Sometimes’ and ‘Often’. Women were clas-
sified as reporting low/medium/high worry using a method 
adapted from Zhang et al. [14]. Participants reporting ‘Not 
at all’ or ‘Rarely’ to both worry questions were classified as 
low worry. Participants reporting ‘Sometimes’ to either or 
both questions were classified as medium worry, and par-
ticipants reporting ‘Often’ to either or both questions were 
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classified as high worry. The breast cancer worry scale was 
administered to participants at baseline and 3-month follow-
up. The Cronbach’s alpha for the scale was 0.73.
Preventive therapy decision
At 3 months, we measured self-reported uptake of tamox-
ifen. Women were asked to tick which of the following cat-
egories applied to them: (1) ‘I decided immediately that I 
did not want to take tamoxifen’; (2) ‘After some thought, I 
decided that I did not want to take tamoxifen’; (3) ‘I am still 
deciding if I want to take tamoxifen’; (4) ‘I met with my 
GP to talk about tamoxifen, and I decided against it’; (5) ‘I 
met with my GP to talk about tamoxifen, but they would not 
prescribe it’; (6) ‘I have a prescription for tamoxifen from 
my GP’; (7) ‘I am currently taking tamoxifen’. Women were 
considered to be using tamoxifen if they ticked categories 6 
or 7, with responses 1–5 indicating no uptake.
Data analysis
The socio-demographic and clinical factors were compared 
between responders and non-responders to the baseline ques-
tionnaire, and responders and non-responders to the 3-month 
questionnaire using Pearson’s Chi-square test. Responses on 
the baseline worry scale were compared between responders 
and non-responders to the 3-month questionnaire using a 
between-subjects t test.
We used Pearson’s Chi-square test to assess for differ-
ences in baseline breast cancer worry (‘low/medium’ vs. 
‘high’) across each of the socio-demographic and clinical 
factors. Fisher’s exact test was used if > 20% of cells had an 
expected count < 5. We conducted a multivariable logistic 
regression model, including all socio-demographic and clini-
cal variables to identify factors associated with high breast 
cancer worry at baseline (vs. ‘low/medium’ worry).
Univariable and multivariable logistic regression models 
examined whether women’s baseline breast cancer worry 
(‘low’, ‘medium’ or ‘high’) was associated with uptake 
of tamoxifen at 3 months. The multivariable model was 
adjusted for all socio-demographic and clinical factors. We 
used a McNemar test to assess for differences in baseline and 
3-month worry across the three different worry groups. We 
used a within-subjects t test to compare mean worry scores 
between baseline and 3-month follow-up.
Sensitivity analyses were conducted to assess if the 
approach used to classify the worry groups affected the 
study’s findings [22]. In the sensitivity analysis, participants 
reporting ‘Not at all’ to both worry questions were classified 
as low worry. Participants reporting ‘Rarely’ to either or 
both worry questions were classified as medium worry, and 
participants reporting ‘Sometimes’ or ‘Often’ to either or 
both worry questions were classified as high worry.
The analysis plan for the study was pre-registered (https:// 
osf. io/ 6dupm). The analysis was conducted in SPSS version 
25, with statistical significance set at a 2-sided p < 0.05.
Results
In total, 732 women consented to participate. For the base-
line survey, 408 (55.7%) women responded, and 258 (63.2%) 
women returned the 3-month follow-up survey. Among the 
408 baseline respondents, 275 (67.4%) attended a family 
history clinic, 49 (12.0%) attended a breast clinic, 25 (6.1%) 
attended a clinical genetic centre, and 59 (14.5%) attended a 
family history clinic with genetics support. Participant char-
acteristics are presented in Table 1.
There were no significant differences between respond-
ers to the baseline survey (408 women) and non-responders 
(324 women) with regard to clinical risk (p = 0.62), socio-
economic status (p = 0.054) or age (p = 0.086). Baseline 
respondents retained at 3 months were more likely to be 
from a higher socioeconomic status (SES) group (p < 0.001). 
There were no significant differences in the mean baseline 
worry scores between responders who only responded to the 
baseline survey compared with those who completed both 
the baseline and 3-month survey (p = 0.234).
Breast cancer worry and participant characteristics
In total, 408 women provided baseline worry data. Among 
these, 39.3% had low baseline breast cancer worry, 39.5% 
had moderate worry, and 21.2% had high worry. For each of 
the worry items, 21.2% worried about developing breast can-
cer ‘often’, while only 3.5% felt their worries about breast 
cancer ‘often’ interfered with their daily activities (Table 1).
In a multivariable logistic regression model (Table 2), 
women from an ethnic minority group were more likely 
to report high breast cancer worry than white women 
(OR = 3.02, 95% CI 1.02, 8.91, p = 0.046). Women who were 
educated to below degree level were more likely to report 
high worry than women educated to degree level or above 
(OR = 2.29, 95% CI 1.28, 4.09, p = 0.005).
We carried out a sensitivity analysis whereby partici-
pants who responded ‘Sometimes’ or ‘Often’ to either or 
both worry questions were categorised into the high worry 
group. In the sensitivity analysis, 52 (12.8%) women were 
categorised as having low worry at baseline. Most women 
(246; 60.7%) were categorised as having high worry, and 
107 (26.4%) were categorised as moderate worry (Supple-
mentary Table 1S). Ethnicity was no longer significantly 
associated with high worry in the sensitivity analysis 
(Table 2S); however, the effect size with education was 
similar (OR = 2.00, 95% CI 1.27, 3.16, p = 0.003). In addi-
tion, women with poor/fair (OR = 2.90, 95% CI 1.43, 5.92, 
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p = 0.003) and good health status (OR = 1.80, 95% CI 1.00, 
3.24, p = 0.050) were more likely to report high breast cancer 
worry than those with excellent health status.
Uptake of preventive therapy and breast cancer 
worry
Among the 258 women who completed the 3-month fol-
low-up questionnaire, 38 (14.7%) had initiated tamoxifen. A 
higher proportion of women in the low worry group (16/103; 
15.5%) and high worry group (8/51; 15.7%) at baseline initi-
ated preventive therapy, compared with the medium worry 
group (14/104; 13.5%). A multivariable logistic regression 
model examined the association of breast cancer worry and 
uptake, after adjusting for all socio-demographic and clinical 
variables. Breast cancer worry was not significantly associ-
ated with tamoxifen initiation in the multivariable model 
(Table 3). No socio-demographic factors were significantly 
associated with uptake in the multivariable model (Table 3).
In the sensitivity analysis, we found that a higher pro-
portion of women categorised as medium worry at baseline 
(13/66; 19.7%) initiated tamoxifen, compared with women 
categorised as high worry (22/155; 14.2%) and low worry 
(3/37; 8.1%). None of the worry levels were significantly 
associated with tamoxifen uptake (Table 3S).
Breast cancer worry at baseline and 3 months
Breast cancer worry was compared between baseline and 
3 months in the sample of women who provided both base-
line and follow-up data (Table 4). A higher proportion of 
participants were categorised as high breast cancer worry 
at baseline (51/258; 19.8%), compared with the proportion 
Table 1  Description of participants demographic, clinical and breast 
cancer worry characteristics at baseline (n = 408)
Demographic, clinical and worry factors Baseline respondents
Age, mean ± SD 45.30 ± 7.82
Age, n (%)
 ≤ 35 years 41 (10)
 36–49 years 259 (63.5)




Ethnic group, n (%)
 White ethnic groups 384 (95.5)





  White and Black Caribbean 2
  White and Black African 1
  Other mixed ethnicity 2
  Any other 2
 Missing, n 6
Education level, n (%)
 Degree or above 176 (44.2)
 Below degree level 222 (55.8)
 Missing, n 10











 Low (most deprived) 120 (29.9)
 Middle 131 (32.7)




 All other employments 60 (14.7)
Marital status, n (%)
 Married or cohabiting 298 (74.3)
 Unmarried 103 (25.7)
 Missing, n 7
Breast cancer worry, n (%)
 Low worry 159 (39.3)
 Medium worry 160 (39.5)
Table 1  (continued)
Demographic, clinical and worry factors Baseline respondents
 High worry 86 (21.2)
 Missing, n 3
Worry about developing breast cancer, n (%)





Worries interfered with daily activities, n (%)





SES socioeconomic status, SD standard deviation
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categorised as high worry at the 3-month follow-up (32/248; 
12.9%). A lower proportion of women were categorised as 
low worry at baseline (103/258; 39.9%) compared with 
3 months (115/248; 46.4%).
There was no significant difference in the proportion of 
women categorised as low, medium and high breast can-
cer worry at baseline compared with the worry categories 
at 3 months (p = 0.077). A within-subjects comparison of 
the average worry level indicated a significant decline in 
worry between baseline (M = 4.09, SD = 1.54) and 3 months 
(M = 3.72, SD = 1.57; p < 0.001).
In the sensitivity analysis, the proportion of women 
categorised as medium worry and high worry decreased 
between baseline (low worry = 14.3%, medium = 25.6%, 
high = 60.1%) and 3-month follow-up (low worry = 29.8%, 
medium = 16.5%, high = 53.6%; p < 0.001).
Discussion
Summary of findings
In this UK prospective study of women at increased risk 
of breast cancer, over one-fifth of women reported high 
worry immediately after an appointment to discuss their 
cancer risk. Breast cancer worry was not consistent over 
time. Higher worry was reported immediately after the 
appointment than at 3-month follow-up, although half of 
our sample maintained a medium or high level of worry at 
Table 2  Breast cancer worry by 
participant characteristics and 
Pearson’s Chi-square test and 
multivariable logistic regression 
model (n = 385)
Bold text indicates statistical significance (P ≤ 0.05)
*Fisher’s exact test
High breast cancer worry (n; %) Chi-square Multivariable
Χ2 P value OR (95% CI) P value
Age 1.21 0.546
 ≤ 35 years 6 (14.6) 0.58 (0.17–2.02) 0.393
 36–49 years 57 (22.2) 1.40 (0.77–2.60) 0.273
 ≥ 50 years 23 (21.5) Ref
Children 0.20 0.656
 Yes 68 (21.7) 1.11 (0.56–2.21) 0.773
 No 18 (19.6) Ref
Ethnic group 6.28 0.032*
 White 76 (19.8) Ref
 Ethnic minority 8 (44.4) 3.02 (1.02–8.91) 0.046
Education level 9.61 0.002
 Degree or above 25 (14.2) Ref
 Below degree level 60 (27.0) 2.29 (1.28–4.09) 0.005
Health status 3.18 0.204
 Poor/fair 25 (26.6) 1.43 (0.58–3.51) 0.434
 Good 49 (20.4) 1.13 (0.50–2.53) 0.767
 Excellent 10 (15.2) Ref
Risk level 2.93 0.219*
 Moderate 45 (18.7) Ref
 High 39 (24.7) 1.24 (0.72–2.11) 0.440
 Unclear 2 (33.3) 1.21 (0.19–7.87) 0.843
SES 7.30 0.026
 Low (most deprived) 32 (26.9) 1.89 (0.96–3.71) 0.066
 Middle 30 (23.1) 1.79 (0.92–3.47) 0.085
 High (least deprived) 21 (14.0) Ref
Employment 1.85 0.173
 Full-time 70 (20.1) Ref
 All other employments 16 (28.1) 1.34 (0.65–2.80) 0.431
Marital status 0.43 0.514
 Married or cohabiting 61 (20.5) 0.69 (0.37–1.28) 0.236
 Unmarried 24 (23.5) Ref
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follow-up. Support for women considering the use of pre-
ventive therapy may be particularly needed among specific 
socio-demographic groups. Women from ethnic minority 
groups and women who had lower educational qualifica-
tions were more likely to report high breast cancer worry 
immediately following their appointment.
Relation to wider literature and implications 
for practice
Women’s worries about developing breast cancer did not 
appear to affect their decisions regarding tamoxifen use. 
Table 3  Uptake of tamoxifen 
by breast cancer worry and 
participant characteristics in the 
univariable and multivariable 
logistic regression model 
(n = 247)
Bold text indicates statistical significance (P ≤ 0.05)
Uptake of tamoxifen (n; %) Univariable Multivariable
OR (95% CI) P value OR (95% CI) P value
Breast cancer worry
 Low worry 16 (15.5) Ref Ref
 Medium worry 14 (13.5) 0.85 (0.39–1.84) 0.672 0.87 (0.38–2.01) 0.744
 High worry 8 (15.7) 1.01 (0.40–2.55) 0.980 1.07 (0.38–3.05) 0.899
Age
 ≤ 35 years 1 (3.8) 0.28 (0.03–2.36) 0.242 0.36 (0.04–3.41) 0.373
 36–49 years 29 (17.3) 1.46 (0.63–3.39) 0.378 1.30 (0.49–3.42) 0.597
 ≥ 50 years 8 (12.5) Ref Ref
Children
 Yes 36 (17.6) 5.43 (1.26–23.34) 0.023 4.66 (0.99–21.99) 0.052
 No 2 (3.8) Ref Ref
Ethnic group
 White 37 (15.0) 1.41 (0.17–11.60) 0.750 1.91 (0.20–18.06) 0.572
 Ethnic minority 1 (11.1) Ref Ref
Education level
 Degree or above 20 (17.2) 1.41 (0.71–2.82) 0.327 1.83 (0.80–4.16) 0.152
 Below degree level 18 (12.9) Ref Ref
Health status
 Poor/fair 5 (10.6) 0.68 (0.20–2.32) 0.538 0.73 (0.20–2.67) 0.629
 Good 25 (16.6) 1.13 (0.46–2.82) 0.787 1.24 (0.47–3.29) 0.666
 Excellent 7 (14.9) Ref Ref
Risk level
 Moderate 24 (15.1) 1.05 (0.52–2.15) 0.885 0.91 (0.42–1.95) 0.910
 High 14 (14.4) Ref Ref
 Unclear 0 – – – –
SES
 Low (most deprived) 7 (11.9) 0.78 (0.30–2.03) 0.613 1.13 (0.41–3.15) 0.814
 Middle 14 (16.3) 1.13 (0.52–2.47) 0.759 1.71 (0.72–4.08) 0.227
 High (least deprived) 16 (14.7) Ref Ref
Employment
 Full-time 32 (14.5) Ref Ref
 All other employments 6 (16.2) 1.14 (0.44–2.96) 0.783 1.50 (0.54–4.18) 0.438
Marital status
 Married or cohabiting 33 (16.7) 2.16 (0.80–5.81) 0.127 1.67 (0.52–5.40) 0.389
 Unmarried 5 (8.5) Ref Ref
Table 4  Proportion of women categorised as low, medium and high 
breast cancer worry at baseline and at 3-month follow-up, in the 
sample of women who provided both baseline and follow-up data 
(n = 258)
Missing worry data for ten respondents at 3-month follow-up
Baseline (n = 258) 3 months (n = 248)
Breast cancer worry groups, n (%)
 Low worry 103 (39.9) 115 (46.4)
 Medium worry 104 (40.3) 101 (40.7)
 High worry 51 (19.8) 32 (12.9)
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These results contrast with previous prospective studies, 
which observed that women who had high worry about 
developing breast cancer were more likely to initiate preven-
tive therapy [10, 11]. We also investigated whether medium 
levels of worry were the optimal level to motivate women to 
initiate tamoxifen, as predicted by the C-SHIP model [23] 
and Yerkes–Dodson law [24]. Previous research found evi-
dence supporting an inverted U-shaped relationship between 
worry and breast cancer screening attendance, whereby 
lower and higher worry was associated with reduced attend-
ance [13–15]. We did not observe a U-shaped relationship 
between worry and uptake in the primary analysis.
There was some evidence to support the inverted 
U-shaped between worry and uptake in the sensitivity anal-
ysis, indicating that the interpretations of this relationship 
will be affected by how worry is categorised. When a higher 
proportion of respondents were categorised into the high 
worry group, the inverted U-shaped was more prominent. 
To assess the direction of this relationship in future research, 
standardised reporting of the classification of low, medium 
and high worry is warranted to allow transparent compari-
sons across cohorts. Additionally, there is a need for future 
studies to be pre-registered to increase the transparency of 
the intended analyses.
Women with lower educational qualifications, and those 
from ethnic minority groups were more likely to report high 
worry about developing breast cancer. These results are 
comparable to previous research that has identified similar 
inequalities in cancer worry in the UK general population 
[18, 19]. The findings indicate inequalities in cancer worry 
may extend to individuals at increased risk of developing the 
disease. It is unclear why these groups experience greater 
worry about breast cancer, but previous evidence suggests 
some ethnic minority groups may be more fearful of the 
social consequences of diagnosis [25]. Further research 
should examine the factors influencing cancer worry in 
higher-risk individuals from these socio-demographic 
groups. Future research should also investigate which ethnic 
minority groups are more likely to experience higher levels 
of cancer worry.
Women with lower educational qualifications may need 
additional support when offered preventive therapy. Women 
educated below degree level have previously been found to 
report lower levels of knowledge on the benefit and harms 
of tamoxifen [26]. The study also found women were more 
likely to initiate tamoxifen if they reported greater knowl-
edge on its benefit and harms [26]. Decision aids may be 
more beneficial in improving health outcomes for disad-
vantaged patients, compared with those with higher literacy 
and from higher SES backgrounds [27]. A meta-analysis of 
randomised control trials found strong evidence to suggest 
cancer-related decision aids increase patients’ knowledge on 
the topic, without increasing anxiety [28]. Decision aids for 
preventive options have also been shown to reduce cancer-
related distress in women at increased risk of breast cancer 
[29]. The development of a decision aid for preventive ther-
apy could address knowledge and worry inequalities among 
women at increased risk of breast cancer.
Reducing patient’s breast cancer worries is important to 
increase their feelings of satisfaction with treatment deci-
sions [10]. One approach is for clinicians to adopt an ‘affec-
tive communication’ style, for example, being emotionally 
supportive with regard to patients’ breast cancer-related wor-
ries when discussing their risk reducing options. An experi-
mental study found that affective communication reduced 
patients’ feelings of anxiety and increased their ability to 
recall information on treatment options [30].
Although our study did not find evidence of an associa-
tion between breast cancer worry and uptake of tamoxifen, 
there may be other influential factors affecting uptake. Our 
analysis was part of the ENGAGE study; a prospective 
investigation of the psychological, clinical and demographic 
factors associated with uptake of breast cancer preventive 
therapy [7, 20, 26]. Previous analyses of the ENGAGE 
cohort have observed women with children [7], and those 
reporting lower concerns about using tamoxifen [20] were 
more likely to initiate preventive therapy. Additionally, we 
previously found that women who felt more informed on 
tamoxifen were less likely to be still deciding on the medi-
cation at three month follow-up [26]. The findings from our 
ENGAGE study contribute to the wider literature on deci-
sion-making in the area of breast cancer preventive therapy. 
We also measured additional patient-reported outcomes that 
have not yet been reported, but have previously been found 
to be associated with increased uptake of preventive therapy. 
These include perceived risk of breast cancer [10] and intru-
sive (i.e. involuntary and repetitive) thoughts and feelings 
on breast cancer [10].
Strengths and limitations
This was the first UK study to investigate breast cancer 
worry and uptake of tamoxifen in a routine clinical setting. 
This context is important as preventive therapy uptake is 
higher in trial settings [31]. Women were recruited from 20 
different centres and four different clinic types across Eng-
land, and recruitment was open for over one year. We used 
a prospective design, which overcomes many of the limita-
tions of previous cross-sectional studies assessing cancer 
worry [8, 9, 32, 33].
This study had limitations. Uptake of preventive therapy 
was self-reported, which may have led us to overestimate 
this behaviour. While our sample size was reasonably large, 
the number of women initiating tamoxifen was low, which 
resulted in low precision for some comparisons. Similarly, 
only 18 ethnic minority participants were recruited, which 
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reduces confidence in the associations between ethnicity, 
worry and uptake. Tamoxifen was the chemoprevention 
agent specified in the questionnaire, as the study was con-
ducted before the introduction of anastrozole in 2017 [5]. 
Our findings should therefore be carefully generalised to 
women considering anastrozole. Additionally, we recruited 
women with a family history of breast cancer, and therefore 
our findings may not be generalisable to other potential users 
of tamoxifen, such as women with high-risk benign lesions.
Over 40% of women who verbally consented to partici-
pate in the study did not complete the baseline survey, which 
may have resulted in selection bias. While we did not find 
significant differences in clinical risk, socioeconomic status 
and age between responders and non-responders to the base-
line survey, there may be other important differences in char-
acteristics between these two groups that we did not measure 
(e.g. ethnicity and education level). There was also evidence 
of a selection bias among responders to the follow-up survey. 
Approximately two-thirds (63%) of participants completed 
the follow-up survey at three months, with respondents from 
higher SES more likely to return the follow-up question-
naire. This may have caused bias in the interpretation of 
our data, as there is evidence to suggest cancer preventive 
healthcare is underutilised by those from lower SES [34, 
35]. Therefore, we may have overestimated rates of uptake 
of preventive therapy in this cohort. Reminder postcards and 
questionnaires were sent to participants to minimise drop-
out rates in our study; however, more intensive retention 
approaches may be needed to improve response rates among 
those at lower SES [36].
Conclusion
In this UK prospective study of women at increased risk of 
breast cancer, most respondents reported medium to high 
levels of breast cancer worry following their initial appoint-
ment to discuss their cancer risk. However, worry was not 
linearly associated with uptake, nor was there a U-shaped 
association. Women with lower educational qualifications 
and ethnic minority women were more likely to report 
higher worry about developing breast cancer. Decision 
aids could be developed specifically for women from these 
socio-demographic groups, to reduce their feelings of cancer 
worry when offered preventive therapy. To advance the field, 
standardised reporting of the classification of low, medium 
and high worry is warranted, and pre-registered studies are 
required.
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